Explore comprehensive insights into antibodies, their functions, and latest research. Stay informed with expert analysis and updates in the field of immunology.
Explore September 2026 antibody biotech deals, including major licensing agreements, ADC collaborations, bispecific antibodies, AI drug discovery, and financing rounds.
Review August 2026 antibody biotech deals, including acquisitions, licensing, ADC partnerships, financing, and AI-driven discovery collaborations.
July 2026 was another active month for the antibody biotech sector, with deal activity ranging from multibillion-dollar acquisitions and antibody licensing agreements to ADC technology deals, AI-driven discovery partnerships, and major private financings. Immunology was a major focus, alongside growing investment in next-generation ADC payloads, multispecific antibodies, and AI-powered antibody discovery.
April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies.
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and autoimmune applications, alongside advancements in targeted protein degradation.
Compare biochemical assays, cell-based assays and immunoassays. See how ELISA, binding tests and functional assays support antibody screening and characterization.
Compare innate and adaptive immunity, key immune cells and organs, and how antibodies connect pathogen recognition with immune defense and diagnostic assays.